Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients
Article Sidebar
Main Article Content
Abstract
Epithelial ovarian cancer (EOC) is one of the most common cancers diagnosed in Indonesian women. A combination of paclitaxel and carboplatin is used to treat EOC as standard chemotherapy which is known to have hematologic toxicities. This study aimed to investigate the effect of combined paclitaxel-carboplatin chemotherapy on hematologic status in EOC patients managed at Dr. Hasan Sadikin General Hospital, Bandung, West Java.
Methods
All patients with confirmed pathological diagnosis of EOC at Dr. Hasan Sadikin General Hospital in the period of 2013 to 2014 were registered. Only patients with complete hematologic data before and after chemotherapy were collected and compared using the paired non-parametric Wilcoxon and McNemar tests.
Results
In total there were 147 patients with EOC (median age 46 ± 12 years), with the most dominant pathological diagnosis of mucinous (32.7%) and serous (29.3%) types. Only 33 patients had hematologic data before the initiation of chemotherapy. There was a significant decrease after chemotherapy including hemoglobin level (12.0 vs 10.9 g/dL, p=0.013), erythrocyte count (4.53 vs 3.74 million/mL, p<0.001), leukocyte count (7,700 vs 4,000/mm3 p<0.001) and platelet count (343,000 vs 215,000/mm3, p<0.001). Interestingly, anemia cases after chemotherapy were predominant (87.9%) compared with erythopenia, leukopenia, thrombocytopenia i.e. 39.4%, 57.6%, and 27.3% respectively.
Conclusions
This study confirmed the hematologic toxicities after paclitaxel-carboplatin chemotherapy in EOC patients treated in Hasan Sadikin General Hospital, West Java. The hemoglobin concentration may serve as prognostic factor. Further studies directed to other factors such as genetic factor for polymorphisms may be encouraged to explore the decrease of the hematologic indices.
Article Details
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
References
Union for International Cancer Control. Epithelial ovarian cancer. Geneva: World Health Organization;2014.
Wahidin M, Noviani R, Hermawan S, et al. Population-based cancer registration in Indonesia. Asian Pac J Cancer Prev 2012;13: 1709-10.
Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA 2011;61:183-203.
Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
Barker S, Weinfeld M, Murray D. DNA–protein crosslinks: their induction, repair, and biological consequences. Mutat Res 2005;589:111-35.
Siregar MFG. Perimenopausal and postmenopausal complaints in paramedics assesed by menopause rating scale in Indonesia. J Dental Med Sci 2009;13:38:42.
Van der Burg M, Vergote I, Onstenk W, et al. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer. Eur J Cancer 2013;49:1254-63.
Pignata S, Cannella L, Leopardo D, et al. Chemotherapy in epithelial ovarian cancer. Cancer Lett 2011; 303:73-83.
Eichbaum MH, Weiss LM, Bruckner T, et al. Prognostic impact of hemoglobin levels before and during carboplatin/taxane-based chemotherapy in patients with primary invasive epithelial ovarian cancer. Med Sci Monit Basic Res 2009;15:CR156-CR63.
Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006;42:2433-53.
Soga N, Onishi T, Arima K, et al. Paclitaxel carboplatin chemotherapy as a second line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases. Int J Urol 2007;14:828-32.
Hasegawa Y, Kawaguchi T, Kubo A, et al. Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. J Thorac Oncol 2011;6: 1881-8.
Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non–small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-5.
Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol 2007;25:3699-704.
Ganti AK, Loberiza FR Jr, Kessinger A. Factors affecting bone marrow toxicity following administration of carboplatin and paclitaxel in patients with non-small cell lung cancer. Anticancer Res 2010;30:1365-9.
Kampan NC, Madondo MT, McNally OM, et al. Paclitaxel and its evolving role in the management of ovarian cancer. BioMed Res Int 2015;2015:413076.
Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 2009;5:745-55.
Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Clin Cancer Res 2007; 13:6410-8.
Arafa HM, Ismail RS, Nabil N, et al. Carnitine deficiency: a causative clue or a sequel in carboplatin myelosuppression. J Cancer Res Updates 2014;3:226-35.
Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006;42:2893-6.
Bergmann TK, Brasch Andersen C, Gréen H, et al. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer. Basic Clin Pharmacol Toxicol 2012; 110:199-204.
Bergmann TK, Gréen H, Brasch-Andersen C, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 2011;67:693-700.
Marsh S, Paul J, King CR, et al. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 2007;25:4528-35.
Qian J, Qu H-Q, Yang L, et al. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. Oncologist 2012;17:1551-61.
Lamba JK, Fridley BL, Ghosh TM, et al. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 2014;15:1565-74.
Gu S, Wu Q, Zhao X, et al. Association of CASP3 polymorphism with hematologic toxicity in patients with advanced non small cell lung carcinoma treated with platinum based chemotherapy. Cancer Sci 2012;103: 1451-9.